Key result
Incident HFrEF and HFpEF share similar mortality risks at one and five years.
Why the study?
Characteristics, outcomes, and guideline adherence for patients with incident HF admissions stratified by HFrEF versus HFpEF had not been defined in a regional Australian setting.
Cohort (n=664)
Yes
Absolute Event Rate: 29% vs 23%
p-value: p=0.15
In a regional Australian cohort, incident heart failure admissions carry a high 5-year mortality of 61% regardless of ejection fraction, with notable underuse of echocardiography and guideline-directed medical therapies.
AIMS: This study aims to (1) define the characteristics of patients with a first admission for heart failure (HF), stratified by type (reduced (HFrEF) vs preserved (HFpEF) ejection fraction) in a regional Australian setting; (2) compare the outcomes in terms of mortality and rehospitalisation and (3) assess adherence to the treatment guidelines. METHODS: We identified all index hospitalisations with HF to John Hunter Hospital and Tamworth Rural Referral Hospital in the Hunter New England Local Health District over a 12 months. We used the recent Australian HF guidelines to classify HFrEF and HFpEF and assess adherence to guideline-directed therapy. The primary outcome of the study was to compare short-term (1 year) and long-term all-cause mortality and the composite of all-cause hospitalisation or all-cause mortality of patients with HFrEF and HFpEF. RESULTS: There were 664 patients who had an index HF admission to John Hunter and Tamworth hospitals in 2014. The median age was 80 years, 47% were female and 22 (3%) were Aboriginal. In terms of HF type, 29% had HFrEF, 37% had HFpEF, while the remainder (34%) did not have an echocardiogram within 1 year of admission and could not be classified. The median follow-up was 3.3 years. HFrEF patients were predominantly male (64%) and in 48% the aetiology was ischaemic heart disease. The 1-year all-cause mortality was 23% in HFpEF subgroup and 29% in HFrEF subgroup (p=0.15). Five-year mortality was 61% in HFpEF and HFrEF patients. Of the HFrEF patients, only 61% were on renin-angiotensin-aldosterone blockers, 74% were on β-blockers and 39% were on aldosterone antagonist. CONCLUSION: HF patients are elderly and about evenly split between HFrEF and HFpEF. In this regional cohort, both HF types are associated with similar 1-year and 5-year mortality following incident HF hospitalisation. Echocardiography and guideline-directed therapies were underused.
No takes yet. Share an insight, caveat, or question.
Al-Omary et al. (2022) conducted a cohort in Incident heart failure (n=664). HFrEF vs. HFpEF was evaluated on 1-year all-cause mortality (p=0.15). Incident heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) were associated with similar 1-year (29% vs 23%, p=0.15) and 5-year (61% vs 61%) mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: